Literature DB >> 24273398

Lorcaserin (Belviq): A Selective Serotonin 5-HT2C Agonist In the Treatment of Obesity.

Ashley Gustafson, Camille King, Jose A Rey.   

Abstract

Entities:  

Year:  2013        PMID： 24273398      PMCID： PMC3828930     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  20 in total

1.  Multicenter, placebo-controlled trial of lorcaserin for weight management.

Authors:  Steven R Smith; Neil J Weissman; Christen M Anderson; Matilde Sanchez; Emil Chuang; Scott Stubbe; Harold Bays; William R Shanahan
Journal:  N Engl J Med       Date:  2010-07-15       Impact factor: 91.245

2.  Annual medical spending attributable to obesity: payer-and service-specific estimates.

Authors:  Eric A Finkelstein; Justin G Trogdon; Joel W Cohen; William Dietz
Journal:  Health Aff (Millwood)       Date:  2009-07-27       Impact factor: 6.301

Review 3.  Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health.

Authors: 
Journal:  Obes Res       Date:  1998-09

4.  Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.

Authors:  Patrick M O'Neil; Steven R Smith; Neil J Weissman; Meredith C Fidler; Matilde Sanchez; Jinkun Zhang; Brian Raether; Christen M Anderson; William R Shanahan
Journal:  Obesity (Silver Spring)       Date:  2012-03-16       Impact factor: 5.002

Review 5.  Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity.

Authors:  Keith J Miller
Journal:  Mol Interv       Date:  2005-10

Review 6.  Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system.

Authors:  Małgorzata Filip; Michael Bader
Journal:  Pharmacol Rep       Date:  2009 Sep-Oct       Impact factor: 3.024

Review 7.  Central serotonin and melanocortin pathways regulating energy homeostasis.

Authors:  Lora K Heisler; Michael A Cowley; Toshiro Kishi; Laurence H Tecott; Wei Fan; Malcolm J Low; James L Smart; Marcelo Rubinstein; Jeffrey B Tatro; Jeffrey M Zigman; Roger D Cone; Joel K Elmquist
Journal:  Ann N Y Acad Sci       Date:  2003-06       Impact factor: 5.691

Review 8.  Serotonin research: contributions to understanding psychoses.

Authors:  Mark A Geyer; Franz X Vollenweider
Journal:  Trends Pharmacol Sci       Date:  2008-09       Impact factor: 14.819

9.  Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.

Authors:  William J Thomsen; Andrew J Grottick; Frederique Menzaghi; Hazel Reyes-Saldana; Stephen Espitia; Diane Yuskin; Kevin Whelan; Michael Martin; Michael Morgan; Weichao Chen; Hussien Al-Shamma; Brian Smith; Derek Chalmers; Dominic Behan
Journal:  J Pharmacol Exp Ther       Date:  2008-02-05       Impact factor: 4.030

Review 10.  Appetite suppressants and valvular heart disease - a systematic review.

Authors:  Yoon K Loke; Sheena Derry; Angharad Pritchard-Copley
Journal:  BMC Clin Pharmacol       Date:  2002-08-23
View more
  14 in total

1.  Identification and Management of Cardiometabolic Risk after Spinal Cord Injury.

Authors:  Mark S Nash; Suzanne L Groah; David R Gater; Trevor A Dyson-Hudson; Jesse A Lieberman; Jonathan Myers; Sunil Sabharwal; Allen J Taylor
Journal:  J Spinal Cord Med       Date:  2019-06-10       Impact factor: 1.985

Review 2.  Obesity: Current and potential pharmacotherapeutics and targets.

Authors:  Vidya Narayanaswami; Linda P Dwoskin
Journal:  Pharmacol Ther       Date:  2016-10-20       Impact factor: 12.310

3.  Identification and Management of Cardiometabolic Risk after Spinal Cord Injury: Clinical Practice Guideline for Health Care Providers.

Authors:  Mark S Nash; Suzanne L Groah; David R Gater; Trevor A Dyson-Hudson; Jesse A Lieberman; Jonathan Myers; Sunil Sabharwal; Allen J Taylor
Journal:  Top Spinal Cord Inj Rehabil       Date:  2018

Review 4.  Review of Advances in Anti-obesity Pharmacotherapy: Implications for a Multimodal Treatment Approach with Metabolic Surgery.

Authors:  Alexis C Sudlow; Carel W le Roux; Dimitri J Pournaras
Journal:  Obes Surg       Date:  2019-12       Impact factor: 4.129

5.  Combination Lorcaserin and Nicotine Patch for Smoking Cessation Without Weight Gain.

Authors:  Jed E Rose; James M Davis
Journal:  Nicotine Tob Res       Date:  2020-08-24       Impact factor: 4.244

6.  Striatal serotonin 2C receptors decrease nigrostriatal dopamine release by increasing GABA-A receptor tone in the substantia nigra.

Authors:  Mary V Burke; Christine Nocjar; Alex J Sonneborn; Andrew C McCreary; Elizabeth A Pehek
Journal:  J Neurochem       Date:  2014-08-21       Impact factor: 5.372

Review 7.  Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases.

Authors:  Giuseppe Di Giovanni; Dubravka Svob Strac; Montse Sole; Mercedes Unzeta; Keith F Tipton; Dorotea Mück-Šeler; Irene Bolea; Laura Della Corte; Matea Nikolac Perkovic; Nela Pivac; Ilse J Smolders; Anna Stasiak; Wieslawa A Fogel; Philippe De Deurwaerdère
Journal:  Front Neurosci       Date:  2016-11-24       Impact factor: 4.677

8.  Cardiovascular Risk Reduction Associated with Pharmacological Weight Loss: A Meta-Analysis.

Authors:  Jesse A Kane; Talha Mehmood; Irsa Munir; Haroon Kamran; Pramod Theetha Kariyanna; Angelina Zhyvotovska; Denis Yusupov; Umer Javed Suleman; Deborah R Gustafson; Samy I McFarlane
Journal:  Int J Clin Res Trials       Date:  2019-01-21

9.  Suppression of cocaine relapse-like behaviors upon pimavanserin and lorcaserin co-administration.

Authors:  Noelle C Anastasio; Dennis J Sholler; Robert G Fox; Sonja J Stutz; Christina R Merritt; James M Bjork; F Gerard Moeller; Kathryn A Cunningham
Journal:  Neuropharmacology       Date:  2020-02-14       Impact factor: 5.250

10.  In Vivo and In Vitro Analyses of Novel Peptidomimetic Disruptors for the Serotonin 5-HT2C Receptor Interaction With Phosphatase and Tensin Homolog.

Authors:  Claudia A Soto; Huang-Chi Du; Robert G Fox; Taegyun Yang; James Hooson; Noelle C Anastasio; Scott R Gilbertson; Kathryn A Cunningham
Journal:  Front Pharmacol       Date:  2019-08-23       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.